About Cure Leukaemia
Founded in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley, Cure Leukaemia helps to bring pioneering drug and transplant treatments to blood cancer patients. The charity helps finance the internationally renowned Centre for Clinical Haematology at Queen Elizabeth Hospital in Birmingham, to fund life-saving, and sometimes world first, clinical trials to treat patients with blood cancer who have exhausted standard treatment options. To date, Cure Leukaemia has helped to treat over 4000 patients by leveraging over £25m worth of revolutionary drugs and funding crucial research nurses to administer these trials.
Without the expert research nurses to ensure patients are constantly monitored and cared for; these trials would not run and patients would miss the opportunity to access potentially life-saving therapies. The aim of Cure Leukaemia is to raise money to fund more research nurses and provide world-class treatment for its patients. Only by funding more nurses in more hospitals, can more blood cancer patients benefit from access to potentially life-saving treatment.
In 2017 Cure Leukaemia raised an additional £1m to fully fund the expansion of the Centre for Clinical Haematology. The transformational £3.4m project has doubled the Centre’s capacity for blood cancer patients treated, clinical trials opened and research nurses employed. Over 75 jobs will be created, and it will allow stem cell transplants to be performed as an outpatient for the first time. Not only will the Centre immediately increase the number of lives saved but also hasten global progress towards establishing effective treatments for all blood cancers within 25 years.
Thanks to a grant of over £2m from the Greater Birmingham and Solihull Local Enterprise Partnership (GBSLEP), work began on the Centre expansion in May 2017 and the Centre reopened in January 2018.
Also in 2017, Cure Leukaemia was selected to be one of Deutsche Bank’s Charities of the Year for 2018 and 2019, a partnership that could be worth at least £2m.